TuHURA Biosciences HURA 深 滬
等待開盤 09-08 09:30:00 美东时间
2.14
+0.040
+1.90%
華盛通- 最 高2.155
- 今 開2.09
- 成交量 36.78万股
- 最 低 2.06
- 昨 收 2.10
- 總市值 1.36亿
- 52周最高 3.43
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 0.41
- 委 比 -2.23%
- 總股本 6372.66万
- 歷史最高 190225.00
- 量 比 2.49
- 振 幅 4.52%
- 歷史最低 0.41
- 每 手 1
- 風險率 0.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TuHURA Biosciences draws additional funds from credit facility
TuHURA Biosciences ( ($HURA) ) has shared an update. TuHURA Biosciences, Inc. p...
09-05 05:51
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler, a seasoned oncology expert with over 30 years of experience at Johnson & Johnson, will also continue his role as a scientific advisor. His extensive background in clinical development and regulatory approvals is expected to significantly benefit Parabilis as it advances its lead drug, zolucatetide, and expands its pipeline of innovativ...
08-25 11:00
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Citizens Reiterates Market Outperform on TuHURA Biosciences, Maintains $9 Price Target
Citizens analyst Silvan Turkcan reiterates TuHURA Biosciences (NASDAQ:HURA) with a Market Outperform and maintains $9 price target.
08-18 20:19
TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 33.33 percent increase over losses of $(0.21) per share from the same period last year.
08-14 20:04
TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administrati...
06-15 19:52
TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 13.33 percent increase over losses of $(0.15) per share
05-16 05:27
美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
TuHURA Biosciences Enters Loan Agreement For Credit Facility Of Up To $50M For Its Pipeline, Ongoing Clinical Trials And General Corporate Expenses
The lender is an affiliate of the Company's largest stockholder, K&V Investment One LLC. Under the terms of the loan agreement, TuHURA will have the ability to draw down monthly on the facility on an as-needed basis
04-22 19:37
美股牛股 | 半导体概念股ALMU大涨超42%！获美政府超400万美元合同，加速半导体量子通信平台发展；RVMD狂飙超41%
半导体概念股ALMU大涨超42%！获美政府合同，加速半导体量子通信平台发展；RVMD狂飙超41%，胰腺癌靶向药III期试验成功，患者生存期接近翻倍>>
04-14 19:23
